Novavax Shines, VIR Antibody Stays in the Game, and CDC Lightens Up

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Pfizer’s Vaccine Passes Kid Test, J&J’s Costly Error, and FTC Challenges Illumina
A Glimpse Into a Price-Controlled Future
AZ Tells Us Its Vaccine is OK. Rebuilding Trust Will Take a While
Burnout Risk Is High. People Need a Break